Kolltan Pharmaceuticals, a privately held biopharmaceutical company, today announced the appointment of Theresa M. LaVallee, Ph.D., as Vice President, Translational Medicine, effective immediately. Dr. LaVallee will report to Jerry McMahon, Ph.D., Kolltan’s President and Chief Executive Officer.
“We are very pleased Theresa is joining the Kolltan management team,” commented Dr. McMahon. “Her leadership experience and record of success in the biotechnology industry and her scientific background in oncology and inflammation make her a great addition as head of our translational medicine effort as we advance our products toward the clinic.”
Dr. McMahon continued, “A primary focus at Kolltan is the creation and development of novel antibody drugs based on new approaches to inhibiting both validated and novel receptor tyrosine kinase, or RTK, targets. This year, we anticipate achieving significant progress in advancing our drug pipeline, as well as bringing in new technologies to enhance our biologics portfolio.”
Dr. LaVallee has more than 25 years of research and industry experience with broad knowledge and proven success in the discovery and development of drug candidates in oncology and inflammation. Dr. LaVallee most recently served as Senior Director, Translational Medicine at MedImmune, the global biologics arm of AstraZeneca. At MedImmune, Dr. LaVallee designed and implemented translational and biomarker strategies for oncology drug development and was a key contributor to IND filings and early clinical development for many product candidates in oncology and inflammatory disease. Previously, she held multiple research positions at EntreMed, including Senior Director, Cell Biology. Dr. LaVallee is author or co-author of more than 40 publications and abstracts, with a focus on receptor tyrosine kinases and their key roles in disease pathways. She received her Ph.D. degree from the University of California, Los Angeles and her B.A. degree from the University of California, Santa Barbara. Dr. LaVallee completed her postdoctoral research at the American Red Cross Holland Laboratory.
About Kolltan Pharmaceuticals
Located adjacent to the Yale Medical School in New Haven, Connecticut, Kolltan is advancing a new generation of therapeutics in oncology and other diseases, based on seminal discoveries made in the laboratory of Dr. Joseph Schlessinger. Kolltan’s primary focus is to create novel biologic agents that can modulate the function of receptor tyrosine kinases (RTKs). Kolltan has approximately 30 employees and, since its inception in 2008, the Company has raised $75 million in equity funding.
For more information about Kolltan Pharmaceuticals, please visit www.kolltan.com.
Justin Jackson, 212-213-0006
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here